{
  "address1": "Lilly Corporate Center",
  "city": "Indianapolis",
  "state": "IN",
  "zip": "46285",
  "country": "United States",
  "phone": "317 276 2000",
  "website": "https://www.lilly.com",
  "industry": "Drug Manufacturers\u2014General",
  "industryDisp": "Drug Manufacturers\u2014General",
  "sector": "Healthcare",
  "sectorDisp": "Healthcare",
  "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.",
  "fullTimeEmployees": 39000,
  "companyOfficers": [
    {
      "maxAge": 1,
      "name": "Mr. David A. Ricks",
      "age": 54,
      "title": "Chairman, CEO & Pres",
      "yearBorn": 1968,
      "fiscalYear": 2022,
      "totalPay": 4416885,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Anat  Ashkenazi",
      "age": 49,
      "title": "Exec. VP & CFO",
      "yearBorn": 1973,
      "fiscalYear": 2022,
      "totalPay": 2125270,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.",
      "age": 48,
      "title": "Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories",
      "yearBorn": 1974,
      "fiscalYear": 2022,
      "totalPay": 2716346,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Anat  Hakim J.D.",
      "age": 53,
      "title": "Exec. VP, Gen. Counsel & Sec.",
      "yearBorn": 1969,
      "fiscalYear": 2022,
      "totalPay": 1979674,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Patrik  Jonsson",
      "age": 55,
      "title": "EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology",
      "yearBorn": 1967,
      "fiscalYear": 2022,
      "totalPay": 1673270,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Donald A. Zakrowski",
      "title": "Chief Accounting Officer & VP of Fin.",
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Diogo  Rau",
      "title": "EVP & Chief Information and Digital Officer",
      "fiscalYear": 2021,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Alonzo  Weems",
      "age": 51,
      "title": "EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer",
      "yearBorn": 1971,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Leigh Ann Pusey",
      "age": 59,
      "title": "Exec. VP of Corp. Affairs & Communications",
      "yearBorn": 1963,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Eric  Dozier",
      "age": 55,
      "title": "Exec. VP of HR & Diversity",
      "yearBorn": 1967,
      "exercisedValue": 0,
      "unexercisedValue": 0
    }
  ],
  "auditRisk": 3,
  "boardRisk": 5,
  "compensationRisk": 1,
  "shareHolderRightsRisk": 9,
  "overallRisk": 5,
  "governanceEpochDate": 1693526400,
  "compensationAsOfEpochDate": 1672444800,
  "maxAge": 86400,
  "priceHint": 2,
  "previousClose": 550.13,
  "open": 548.81,
  "dayLow": 547.6273,
  "dayHigh": 555.4856,
  "regularMarketPreviousClose": 550.13,
  "regularMarketOpen": 548.81,
  "regularMarketDayLow": 547.6273,
  "regularMarketDayHigh": 555.4856,
  "dividendRate": 4.52,
  "dividendYield": 0.0082,
  "exDividendDate": 1691971200,
  "payoutRatio": 0.5877,
  "fiveYearAvgDividendYield": 1.59,
  "beta": 0.315006,
  "trailingPE": 76.357834,
  "forwardPE": 43.624405,
  "volume": 2353602,
  "regularMarketVolume": 2353602,
  "averageVolume": 2877822,
  "averageVolume10days": 3453510,
  "averageDailyVolume10Day": 3453510,
  "bid": 550.21,
  "ask": 550.45,
  "bidSize": 900,
  "askSize": 900,
  "marketCap": 522624827392,
  "fiftyTwoWeekLow": 304.88,
  "fiftyTwoWeekHigh": 601.84,
  "priceToSalesTrailing12Months": 17.706793,
  "fiftyDayAverage": 520.0756,
  "twoHundredDayAverage": 415.11905,
  "trailingAnnualDividendRate": 4.22,
  "trailingAnnualDividendYield": 0.007670914,
  "currency": "USD",
  "enterpriseValue": 510826938368,
  "profitMargins": 0.22014,
  "floatShares": 897487590,
  "sharesOutstanding": 949294976,
  "sharesShort": 5617552,
  "sharesShortPriorMonth": 4781769,
  "sharesShortPreviousMonthDate": 1690761600,
  "dateShortInterest": 1693440000,
  "sharesPercentSharesOut": 0.0058999998,
  "heldPercentInsiders": 0.00153,
  "heldPercentInstitutions": 0.83985,
  "shortRatio": 1.84,
  "shortPercentOfFloat": 0.0070999996,
  "impliedSharesOutstanding": 949294976,
  "bookValue": 12.303,
  "priceToBook": 44.748432,
  "lastFiscalYearEnd": 1672444800,
  "nextFiscalYearEnd": 1703980800,
  "mostRecentQuarter": 1688083200,
  "earningsQuarterlyGrowth": 0.851,
  "netIncomeToCommon": 6497500160,
  "trailingEps": 7.21,
  "forwardEps": 12.62,
  "pegRatio": 2.32,
  "lastSplitFactor": "2:1",
  "lastSplitDate": 876960000,
  "enterpriseToRevenue": 17.307,
  "enterpriseToEbitda": 52.312,
  "52WeekChange": 0.7890407,
  "SandP52WeekChange": 0.18466556,
  "lastDividendValue": 1.13,
  "lastDividendDate": 1691971200,
  "exchange": "NYQ",
  "quoteType": "EQUITY",
  "symbol": "LLY",
  "underlyingSymbol": "LLY",
  "shortName": "Eli Lilly and Company",
  "longName": "Eli Lilly and Company",
  "firstTradeDateEpochUtc": 76253400,
  "timeZoneFullName": "America/New_York",
  "timeZoneShortName": "EDT",
  "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b",
  "messageBoardId": "finmb_285467",
  "gmtOffSetMilliseconds": -14400000,
  "currentPrice": 550.54,
  "targetHighPrice": 640.0,
  "targetLowPrice": 340.0,
  "targetMeanPrice": 569.28,
  "targetMedianPrice": 600.0,
  "recommendationMean": 1.9,
  "recommendationKey": "buy",
  "numberOfAnalystOpinions": 24,
  "totalCash": 2941299968,
  "totalCashPerShare": 3.271,
  "ebitda": 9765000192,
  "totalDebt": 18953500672,
  "quickRatio": 0.633,
  "currentRatio": 1.128,
  "totalRevenue": 29515499520,
  "debtToEquity": 169.997,
  "revenuePerShare": 32.763,
  "returnOnAssets": 0.10182,
  "returnOnEquity": 0.65602994,
  "grossProfits": 21911600000,
  "freeCashflow": 5056487424,
  "operatingCashflow": 5740599808,
  "earningsGrowth": 0.857,
  "revenueGrowth": 0.281,
  "grossMargins": 0.77769995,
  "ebitdaMargins": 0.33084,
  "operatingMargins": 0.28116,
  "financialCurrency": "USD",
  "trailingPegRatio": 1.4502
}